Use

This comprehensive prognostic panel is used for determining prognosis and risk stratification in patients with chronic lymphocytic leukemia (CLL). It integrates multiple prognostic markers—including chromosome analysis, a 6‑marker FISH panel, IgVH gene mutation analysis, ZAP‑70, CD38, and serum β2‑microglobulin—to generate a patient‑specific overall risk interpretation that reflects the combined prognostic power of each marker ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq41?utm_source=openai)).